Anzeige
Mehr »
Sonntag, 10.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A417NW | ISIN: US03835L5049 | Ticker-Symbol: AP81
München
08.08.25 | 08:05
1,950 Euro
-0,51 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APTEVO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
APTEVO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur APTEVO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrRedChip Companies, Inc.: Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV249ORLANDO, FLORIDA / ACCESS Newswire / August 8, 2025 / RedChip Companies will air interviews with Aptevo Therapeutics, Inc. (NASDAQ:APVO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip...
► Artikel lesen
25.07.Aptevo Therapeutics files to sell 8.25M shares of common stock for holders3
25.07.Aptevo Therapeutics Inc. - S-1, General form for registration of securities2
24.07.Aptevo Therapeutics Inc. - 8-K, Current Report2
01.07.Aptevo erlangt nach Kapitalerhöhung von 15,9 Millionen US-Dollar wieder Nasdaq-Konformität3
30.06.Aptevo Therapeutics Inc. - 8-K, Current Report1
APTEVO THERAPEUTICS Aktie jetzt für 0€ handeln
20.06.Aptevo Therapeutics closes $8 million registered direct offering2
20.06.Aptevo Therapeutics schließt registrierte Direktplatzierung über 8 Millionen US-Dollar ab3
20.06.Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules285SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based...
► Artikel lesen
20.06.Aptevo adds Nectin-4 targeting therapy to CD3 bispecific portfolio3
20.06.Aptevo Therapeutics: Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers259Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO455 targets Nectin-4+ cancers, joins mipletamig...
► Artikel lesen
18.06.Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer6
18.06.Aptevo Therapeutics announces $8M at-the-market equity offering with warrants; shares more than double5
18.06.Aptevo Therapeutics raises $8 million in registered direct offering8
18.06.Aptevo Therapeutics stock soars after impressive AML treatment results2
18.06.Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules269SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary...
► Artikel lesen
18.06.Aptevo reports 85% remission rate in frontline AML trial7
18.06.Aptevo Therapeutics: Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML1.00185% remission rate observed in evaluable frontline AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed...
► Artikel lesen
17.06.Aptevo Therapeutics Inc. - 8-K, Current Report1
16.06.Aptevo Therapeutics Inc. - S-1, General form for registration of securities2
Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1